Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Tyrosine Kinase Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis, 2022
Tyrosine Kinase Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis, 2022
Tyrosine Kinases are enzymes responsible for the activation of proteins by signal transduction cascades. Depending on the type of tyrosine kinase receptor, the mechanism of action of TKIs (Tyrosine Kinase Inhibitors) varies. Some of the TKIs bind to the extracellular domain of the RTKs (receptor tyrosine kinases) and prevent them from dimerizing and activating each other by cross-phosphorylation, thereby blocking the downstream signaling pathways that promote cell proliferation and survival. Other TKIs bind to the intracellular domain of the NRTKs (non-receptor tyrosine kinases) and compete with ATP to prevent the transfer of phosphate groups to the substrate proteins, thus inhibiting their activation. TKIs are primarily used for the treatment of lung cancer, breast cancer, renal cancer, and chronic myeloid leukemia. AstraZeneca, Novartis, Roche, Boehringer Ingelheim, and Bayer are the key companies that are currently providing tyrosine kinase inhibitors for the treatment of cancer patients in the market.
Key Developments
Approved Drugs - Tyrosine kinase inhibitors
Pipeline Drugs - Tyrosine Kinase Inhibitors
Clinical Activity and Development of Tyrosine kinase inhibitors
With more than 50 FDA-approved drugs on the market for tyrosine kinase inhibition and further ongoing research and clinical trials by leading pharmaceutical companies, the market will see growth in recent future.
The tyrosine kinase inhibitors market mainly consists of BCR-ABL TKIs, EGFR TKIs, VEGFR TKIs, BRAF kinase inhibitors, and ROS1 inhibitors. The molecules of tyrosine kinase inhibitors treat several kinds of cancer including HER2-positive breast cancer, brain-metastatic breast cancer, gastrointestinal stromal tumors, Waldenstrom macroglobulinemia, kidney cancer, chronic lymphocytic leukemia, chronic myeloid leukemia, and non-small cell lungcancer. According to an article published in 2022, Imatinib, a tyrosine kinase inhibitor was successful in inhibiting cellular tyrosine kinase as well as viral fusion, thereby blocking the COVID-19 virus replication.
J&J Services’s TKI, Imbruvica has seen a decline in its sales in the year 2022 to US$ 3,784 from US$ 4,369 due to competitive pressures and market suppression. Retevmo by J&J is protected by a compound patent (2037), and by data protection (2031) in the USA and European countries, and by a compound patent (2038) and by data protection (2029) in Japan. Breast cancer is the most common cancer occurring in women (22,61,419 patients globally) having the highest number of cancer rates in the USA (253,465 patients), followed by France (58,083), and Australia (19,617 patients). Similarly, some of the other indications of TKI such as kidney cancer have the maximum cancer rates in the USA (69,569 patients), followed by France (14,705) demonstrating them as the market with major growth potential for TKI.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Rybrevant (Amivantamab), Imbruvica (Ibrutinib), Retevmo (Selpercatinib), Exkivity (Mobocertinib), Vijoice (Alpelisib) and Verzenio (Abemaciclib) are some of the approved Tyrosine kinase inhibitors.
The global sale of Imbruvica for 2022 was US$ 5,784 million.
AstraZeneca, Novartis, Roche, Boehringer Ingelheim, and Bayer are a few major players in the Tyrosine kinase inhibitors space.
More than 23,00,000 women are affected by breast cancer globally.
HER2-positive breast cancer, brain-metastatic breast cancer, gastrointestinal stromal tumors, Waldenstsrom macroglobulinemia, kidney cancer, chronic lymphocytic leukemia, chronic myeloid leukemia, and non-small cell lung cancer are some of the indications on which companies could focus on for the expansion of Tyrosine kinase inhibitors market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.